The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2018 | Increased survival in metastatic NSCLC patients on immunochemotherapy seen in trials
Marina Garassino, MD, of the National Cancer Institute of Milan, Milan, Italy, brings optimistic results from the latest clinical trials investigating the combination of chemotherapy and immunotherapy in patients with metastatic non-small cell lung cancer, with positive outcomes extending even to patients with squamous histology. Positive trial outcomes include a consistently increased overall and progression-free survival in patients, indicating a promising outlook for treatment. This interview was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.
